-
-
-
-
-
-
-
VBI Vaccines Partner Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination With PEG-IFNα for the Treatment of Chronic Hepatitis B
-
-
-
-
-
-
-
Brii Biosciences Broadens its Leadership in Hepatitis B with a Portfolio Now Addressing Disease's Burdens from Prevention to Cure
-
-
-
-
-
-
-
VBI Vaccines Announces Poster Presentation at EASL 2023
-
-
-
-
-
-
-
VBI Vaccines Reports Full Year 2022 Financial Results
-
-
-
-
-
-
-
VBI Vaccines Secures $100 Million Debt Facility From K2 HealthVentures
-
-
-
-
-
-
-
VBI Vaccines Announces New Long-Term Follow-Up Clinical Data for its 3-Antigen Adult Hepatitis B Vaccine Presented at EASL 2022
-
-
-
-
-
-
-
VBI Vaccines Announces European Commission Marketing Authorisation for PreHevbri™, a 3-Antigen Adult Hepatitis B Vaccine
-
64,524 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

